13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001583977
Total reported value
$2.0B
$2.0B
46 檔
38.4%
In Q1 2026, Cormorant Asset Management, LP's U.S. equity holdings reached a combined market value of $2.0B, distributed across 46 disclosed stock positions.
Cormorant Asset Management, LP executed strategic sector rebalancing during Q1 2026, establishing 17 new positions while fully exiting 6 holdings and trimming 17 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 14.33% | -3.35% | -6.79% | |
| 2 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 8.04% | -1.06% | — | |
| 3 | EYPT | Eyepoint Inc | Stock-Other | 5.35% | -0.22% | — | |
| 4 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.16% | +0.07% | -0.76% | |
| 5 | ERAS | Erasca Inc | Stock-Other | 4.71% | +0.92% | — | |
| 6 | RAPP | Rapport Therapeutics Inc | Stock-Other | 4.65% | +1.02% | -2.31% | |
| 7 | ALMS | Alumis Inc | Stock-Other | 4.37% | +0.37% | +8.63% | |
| 8 | ABVX | Abivax Sa-adr | Stock-Other | 4.25% | +0.36% | -43.70% | |
| 9 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 4.19% | -0.99% | +2.87% | |
| 10 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.00% | -0.25% | — | |
| 11 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 3.88% | -0.64% | — | |
| 12 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 3.29% | -1.92% | +60.00% | |
| 13 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.17% | -1.07% | -29.17% | |
| 14 | BIOA | Bioage Labs Inc | Stock-Other | 2.54% | +0.46% | +41.65% | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.09% | -2.09% | EXIT | |
| 16 | DMRA | Damora Therapeutics Inc | Stock-Other | 1.98% | -0.65% | — | |
| 17 | MBX | Mbx Biosciences Inc | Stock-Other | 1.68% | -0.12% | — | |
| 18 | INSM | Insmed Inc | Stock-Healthcare | 1.56% | -1.15% | -30.91% | |
| 19 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.53% | -0.66% | -5.00% | |
| 20 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.50% | +0.58% | — | |
| 21 | PHVS | Pharvaris N.V. | Stock-Other | 1.42% | -0.09% | -7.66% | |
| 22 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.31% | +1.29% | — | |
| 23 | AGMB | Agomab Therapeutics NV | Stock-Other | 1.30% | +0.34% | — | |
| 24 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.12% | -1.12% | EXIT | |
| 25 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.11% | +0.02% | — | |
| 26 | ASND | Ascendis Pharma A/S | Stock-Other | 1.09% | -1.09% | EXIT | |
| 27 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.04% | -0.18% | — | |
| 28 | ANL | Adlai Nortye Ltd-adr | Stock-Other | 1.01% | +1.33% | — | |
| 29 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.79% | -0.79% | EXIT | |
| 30 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.79% | -0.47% | -10.00% | |
| 31 | BHVN | Biohaven Ltd. | Stock-Other | 0.75% | +1.24% | +17500.00% | |
| 32 | CABA | Cabaletta Bio Inc | Stock-Other | 0.74% | +0.06% | +25.00% | |
| 33 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 0.66% | +0.05% | — | |
| 34 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.53% | -0.29% | -10.00% | |
| 35 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.48% | -0.09% | — | |
| 36 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.46% | -0.22% | -16.67% | |
| 37 | ✓ | Zura Bio LTD | Stock-Other | 0.43% | -0.43% | EXIT | |
| 38 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.42% | -0.42% | EXIT | |
| 39 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.42% | -0.21% | — | |
| 40 | COGT | Cogent Biosciences Inc | Stock-Other | 0.39% | -0.19% | -11.11% | |
| 41 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.33% | -0.33% | EXIT | |
| 42 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.31% | -0.10% | — | |
| 43 | PCVX | Vaxcyte Inc | Stock-Other | 0.29% | -0.14% | -20.00% | |
| 44 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.24% | -0.06% | -12.50% | |
| 45 | RLYB | Rallybio CORP | Stock-Other | 0.18% | -0.18% | EXIT | |
| 46 | CNTX | Context Therapeutics Inc | Stock-Other | 0.07% | -0.07% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALMS | Alumis Inc | +2.7% | +8.63% | Add |
| 2 | MLTX | Moonlake Immunotherapeutics | +1.5% | +2.87% | Add |
| 3 | EWTX | Edgewise Therapeutics Inc | +1.4% | -0.76% | Trim |
| 4 | PRAX | Praxis Precision Medicines I | +1.4% | -6.79% | Trim |
| 5 | BIOA | Bioage Labs Inc | +1.3% | +41.65% | Add |
| 6 | BHVN | Biohaven Ltd. | +0.7% | +17500.00% | Add |
| 7 | ORKA | Oruka Therapeutics Inc | +0.6% | — | Unchanged |
| 8 | 260 | Centessa Pharmaceuticals-adr | +0.6% | -20.75% | Trim |
| 9 | RAPP | Rapport Therapeutics Inc | +0.4% | -2.31% | Trim |
| 10 | CABA | Cabaletta Bio Inc | +0.3% | +25.00% | Add |
| 11 | CRBP | Corbus Pharmaceuticals Holdi | +0.2% | — | Unchanged |
| 12 | OLMA | Olema Pharmaceuticals Inc | +0.1% | +60.00% | Add |
| 13 | ASND | Ascendis Pharma A/S | +0.1% | -5.00% | Trim |
| 14 | DRUG | Bright Minds Biosciences Inc | +0.1% | — | Unchanged |
| 15 | MBX | Mbx Biosciences Inc | +0.1% | — | Unchanged |
| 16 | PHVS | Pharvaris N.V. | 0% | -7.66% | Trim |
| 17 | COGT | Cogent Biosciences Inc | 0% | -11.11% | Trim |
| 18 | PCVX | Vaxcyte Inc | 0% | -20.00% | Trim |
| 19 | AMLX | Amylyx Pharmaceuticals Inc | 0% | -12.50% | Trim |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | -0.1% | -5.00% | Trim |
| 21 | ARQT | Arcutis Biotherapeutics Inc | -0.1% | -10.00% | Trim |
| 22 | TARS | Tarsus Pharmaceuticals Inc | -0.2% | -10.00% | Trim |
| 23 | CRNX | Crinetics Pharmaceuticals In | -0.2% | -16.67% | Trim |
| 24 | AXSM | Axsome Therapeutics Inc | -0.2% | -33.33% | Trim |
| 25 | INSM | Insmed Inc | -0.7% | -30.91% | Trim |
| 26 | BBIO | Bridgebio Pharma Inc | -1.1% | -29.17% | Trim |
| 27 | EYPT | Eyepoint Inc | -1.6% | — | Unchanged |
| 28 | BBOT | Bridgebio Oncology Therapeut | -2.3% | — | Unchanged |
| 29 | ABVX | Abivax Sa-adr | -4.2% | -43.70% | Trim |
| 30 | QQQ | Invesco Qqq Trust Series 1 | — | EXIT | Sold out |
| 31 | IWM | Ishares Russell 2000 ETF | — | EXIT | Sold out |
| 32 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 33 | ERAS | Erasca Inc | — | NEW | New buy |
| 34 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 35 | DMRA | Damora Therapeutics Inc | — | NEW | New buy |
| 36 | ✓ | Engene Holdings Inc | — | EXIT | Sold out |
| 37 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 38 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
| 39 | MAZE | Maze Therapeutics Inc | — | NEW | New buy |
| 40 | ROIV | Roivant Sciences Ltd. | — | NEW | New buy |
| 41 | ANL | Adlai Nortye Ltd-adr | — | NEW | New buy |
| 42 | GHRS | GH Research PLC | — | EXIT | Sold out |
| 43 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 44 | ✓ | Helix Acquisition CORP Iii | — | NEW | New buy |
| 45 | FTH | Faeth Therapeutics Inc | — | NEW | New buy |
| 46 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 47 | ✓ | Zura Bio LTD | — | NEW | New buy |
| 48 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
| 49 | GLUE | Monte Rosa Therapeutics Inc | — | NEW | New buy |
| 50 | ARWR | Arrowhead Pharmaceuticals In | — | NEW | New buy |
According to official SEC Form 13F filings, Cormorant Asset Management, LP reported a total U.S. public equity portfolio value of $2.0B across 46 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, BBOT, EYPT) accounted for 38.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
ERAS
市值: $93.8M
Top Position Liquidated / Trimmed
QQQ
前期市值: $153.6M
During Q1 2026, Cormorant Asset Management, LP's top holdings by market value included PRAX (14.3%)、BBOT (8.0%)、EYPT (5.3%). The largest single position, PRAX, represented 14.3% of total portfolio value.
In Q1 2026, Cormorant Asset Management, LP made 46 total portfolio adjustments, initiating 17 new buys, adding to 6 positions, trimming 17 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.